DOCSLIB.ORG

Doxycycline 50Mg and 100Mg Capsules Numbers of Different Cell Types in the Blood

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Doxycycline 50Mg and 100Mg Capsules Numbers of Different Cell Types in the Blood • Skin that is more sensitive to sunlight than Reporting of side effects normal. You may get a skin rash, itching, redness If you get any side effects, talk to your doctor, or severe sunburn. If this happens, stop taking pharmacist or nurse. This includes any possible side Package leaflet: Information for the user the medicine and tell your doctor. effects not listed in this leaflet. You can also report • Inflammation and/or ulcers of the gullet. side effects directly via the Yellow Card Scheme at: • Blood disorders. These are due to changes in www.mhra.gov.uk/yellowcard or search for MHRA Doxycycline 50mg and 100mg capsules numbers of different cell types in the blood. Yellow Card in the Google Play or Apple App Store. Symptoms may include tiredness, easy bruising By reporting side effects, you can help provide or infections. more information on the safety of this medicine. • Low blood pressure. Read all of this leaflet carefully before you Mountain spotted fever, travellers’ diarrhoea, malaria and leptospirosis (a bacterial infection). • Increased heart rate. 5 How to store Doxycycline capsules start taking this medicine because it contains • Aches in the joints or muscles. important information for you. Your doctor may want you to take Doxycycline Keep out of the sight and reach of children. Store capsules to treat another infection not listed above. • Stomach pain and diarrhoea. below 25ºC in a dry place. • Keep this leaflet. You may need to read it The side effects listed below may go away during You may also be prescribed an additional medicine Do not use Doxycycline capsules after the expiry again. to take with Doxycycline capsules to treat your treatment as your body adjusts to the medicine. date stated on the label/carton/bottle. The expiry • If you have any further questions, ask your Tell your doctor if any of these side effects continue infection. You must talk to your doctor if you do not date refers to the last day of that month. doctor, pharmacist or nurse. feel better or if you feel worse. to bother you: Medicines should not be disposed of via • This medicine has been prescribed for you Common: may affect up to 1 in 10 people wastewater or household waste. Ask your only. Do not pass it on to others. It may harm 2 What you need to know before you • feeling or being sick pharmacist how to dispose of medicines no longer them, even if their signs of illness are the same • worsening of a disease called systemic lupus required. These measures will help to protect the take Doxycycline capsules as yours. Do not take Doxycycline capsules if you: erythematous (SLE). This is an allergic condition environment. • If you get any side effects, talk to your doctor, which causes joint pain, skin rash and fever • are allergic to doxycycline, other similar pharmacist or nurse. This includes any headache 6 Contents of the pack and other antibiotics (such as minocycline or tetracycline) • pericarditis (inflammation affecting the heart) possible side effects not listed in this leaflet. or any of the other ingredients of this medicine information See section 4. (listed in section 6) Uncommon: may affect up to 1 in 100 people • are pregnant or trying to become pregnant • heartburn What Doxycycline capsules contain • The active substance (the ingredient that makes What is in this leaflet • are breast-feeding. • vaginal infection You should not use Doxycycline capsules during the capsule work) is Doxycycline hyclate. Each 1 What Doxycycline capsules are and Rare: may affect up to 1 in 1,000 people capsule contains either 50mg or 100mg of periods of tooth development (pregnancy, infancy • anxiety Doxycycline base. what they are used for or in children below 8 years old) as such use may • difficulty in swallowing, sore or painful tongue • The other ingredients are gelatin, magnesium 2 What you need to know before you lead to permanent discolouration (yellow-grey- or mouth stearate, shellac glaze, sodium lauryl sulfate, take Doxycycline capsules brown). • skin reddening (flushing) starch, quinoline yellow (E104), erythrosine 3 How to take Doxycycline capsules There may be circumstances (e.g. severe or life- • a ringing or buzzing noise in the ear (E127), patent blue V (E131), titanium dioxide threatening conditions), where your physician 4 Possible side effects • soreness and itching of the rectal and/or genital (E171), iron oxide black (E172), and propylene may decide that the benefits outweigh this risk in area glycol. 5 How to store Doxycycline capsules children below 8 years and Doxycycline capsules • inflammation of the bowel 6 Contents of the pack and other should be prescribed. • bulging fontanelles (soft spot on head) of infants What Doxycycline capsules look like and information Warnings and precautions • increased pressure in the skull (severe headache contents of the pack Talk to your doctor or pharmacist before taking with change in vision) Doxycycline 50mg capsules are green and white 1 Doxycycline capsules if any of the following apply • inflammation and damage to the liver hard gelatin capsules printed “C” and “DV” in black. What Doxycycline capsules are and to you: • abnormal liver function tests Doxycycline 100mg capsules are green hard what they are used for • you are likely to be exposed to strong sunlight • discolouration of the thyroid tissue when given gelatin capsules printed “C” and “DW” in black. Doxycycline is an antibiotic belonging to a group or UV light (e.g. on a sun bed). You should avoid for long periods. The medicine does not impair Doxycycline 50mg capsules are available in pack of medicines called tetracyclines. It is used to treat exposure to strong sunlight while taking this thyroid function sizes of 28 capsules. many different types of infections including: medicine as your skin may be more sensitive to • loosening of the nail from the nail bed after Doxycycline 100mg capsules are available in pack • Chest, lung or nasal infections e.g. bronchitis, sunburn than normal. exposure to the sun sizes of 8 & 50 capsules. pneumonia, sinusitis • you have kidney or liver problems. • increased levels of urea in the blood • Urinary tract infections (the passage through Marketing Authorisation Holder and • you have myasthenia gravis (a disease which • yellow skin and eyes (jaundice), inflammation of which urine passes) e.g. cystitis, urethritis Manufacturer causes unusual tiredness and weakness of the pancreas • Acne (a skin condition) Accord Barnstaple, EX32 8NS, UK certain muscles, particularly in the eyelid). • upset stomach, loss of appetite, diarrhoea (this • Eye infections This leaflet was last revised in October 2020 • you have porphyria (a rare disease of blood may occur up to two or three months after the • Sexually transmitted diseases e.g. gonorrhoea, pigments). last dose), stomach pain syphilis, chlamydia If you would like a • you have (or have ever had) systemic lupus • darker patches on your skin. • Fevers associated with louse or tick bites leaflet with larger • Malaria, when chloroquine is not effective erythematosus (an allergic condition that causes Not known: frequency cannot be estimated from text, please contact Doxycycline capsules are also used to prevent joint pain, skin rashes and fever). This condition the available data certain infections developing, these are scrub may be worsened by taking Doxycycline • discolouration and/or lack of growth of teeth 01271 385257. typhus (a disease carried by small insects) Rocky capsules. Continued top of next column 50994082 BBBA9053 Continued top of next column Continued over page 296x210 Leaflet Reel Fed Bi Fold Profile (BST) page 4 page 1 Doxycycline Capsules 50, 100mg x 8, 28, 56 (UK) Doxycycline hyclate 50mg and 100mg Capsules PIL - UK JDE No.: 50994082 approved for print/date Item number: BBBA9053 Colours Non Printing Colours Dimensions: 296x210 (Reel Fed) 1. Black 1. Profile Originator: M.Doak Dimensions: 296 x 210mm 2. 2. Component: Leaflet for Blisters Origination Date: 25/09/2020 Min Body Text Size: 9pt Revision Date: 22/10/2020 Supplier: Accord Barnstaple 3. 3. Pharmacode: 3792 Revised By: M.Doak 4. 5. Proof Round Date Sent: Technical Date sent: N/A 6. 25/09/20 5 Approval Date received: N/A Technologist: T. Hull [email protected] Technically Approved Cartons and label leaflets only (labels only when specified) German GTIN 14 (incorporating PZN): N/A * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 7 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.02.2020 • you are suspected of having syphilis. Your Pregnancy and breast-feeding Adults and children aged 12 years to less than If you forget to take Doxycycline capsules doctor will continue to monitor you after your If you are pregnant or breast-feeding, think you 18 years: If you forget to take a capsule, take it as soon as you treatment has stopped. may be pregnant or are planning to have a baby 200mg on the first day, then 100 mg daily. The can. Take your next capsule at the right time. Do • you have diarrhoea or usually get diarrhoea ask your doctor or pharmacist for advice before length of treatment is dependent on the infection not take a double dose to make up for a forgotten when you take antibiotics or have suffered from taking this medicine. being treated. dose. problems with your stomach or intestines. If Doxycycline capsules must not be taken if you are Acne: 50mg daily for 6-12 weeks, with food or a If you stop taking Doxycycline capsules you develop severe or prolonged or bloody pregnant or breast-feeding. drink. If you stop taking the capsules too soon, the diarrhoea during or after using Doxycycline Driving and using machines infection may return.
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Options
    Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment.
    [Show full text]
  • Doxycycline/Minocycline Step Therapy Criteria Program Summary
    Doxycycline/Minocycline Step Therapy Criteria Program Summary This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the use of both cost-effective preferred doxycycline and minocycline products prior to the use of nonpreferred brand or generic doxycycline or minocycline products and to accommodate for use of brand nonpreferred doxycycline or minocycline products when the generic products cannot be used due to previous trial, documented intolerance, FDA labeled contraindication, or hypersensitivity. Requests for nonpreferred doxycycline and minocycline products will be reviewed when patient-specific documentation has been provided. TARGET DRUGS Doxycycline Products: Acticlate™ (doxycycline hyclate tablet) Adoxa (doxycycline monohydrate tablet, capsule) Doryx, Doryx MPC® (doxycycline hyclate delayed-release tablet)a Doxycycline (doxycycline hyclate delayed-release capsulea, doxycycline hyclate tablet, doxycycline monohydrate delayed release capsule) Monodox (doxycycline monohydrate capsule) Oracea (doxycycline monohydrate delayed-release capsule) Vibramycin (doxycycline hyclate capsule, doxycycline monohydrate suspension, doxycycline calcium syrup Minocycline Products: Minocin (minocycline capsule) minocycline tablet Solodyn (minocycline extended-release tablet)a a - available as a generic; designated target PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Brand and Nonpreferred generic doxycycline and minocycline products will be approved when BOTH of the following are met: 1. ONE of the following: a. The patient’s medication history includes use of a preferred generic doxycycline product OR b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a preferred generic doxycycline product AND 2. ONE of the following is met: a. The patient’s medication history includes use of a preferred generic minocycline product OR b.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • Doxycycline Hyclate) Capsule, Delayed Release Pellets
    Doryx (doxycycline hyclate) Capsule, Delayed Release Pellets To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORYX® and other antibacterial drugs, DORYX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad- spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration. The structural formula for doxycycline hyclate is with a molecular formula of C22H24N2O8, HCl, ½ C2H6O, ½ H2O and a molecular weight of 512.9. The chemical designation for doxycycline hyclate is [4S (4aR, 5S, 5aR, 6R, 12aS)]-4-(dimethylamino)-1,4,4a, 5,5a, 6, 11,12a-octahydro-3, 5,10,12,12a- pentahydroxy-6-methyl-1, 11-deoxonapthtacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Inert ingredients in the capsule formulation are: lactose; microcrystalline cellulose; povidone; starch wheat; magnesium stearate; cellulosic polymer coating. The capsule shell and/or band contains FD and C blue No.1; FD and C yellow No. 6; D and C yellow No.10; gelatin, silicon dioxide; sodium lauryl sulfate; titanium dioxide. CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations and in a biologically active form.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Reporting Protocol (Version 4)
    9 March 2021 EMA/210691/2015 Rev. 4 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Reporting Protocol (version 4) Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us An agency of the European Union Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ............................................................................................ 3 1.1. Terms of reference ............................................................................................. 3 1.2. Approach .......................................................................................................... 4 1.3. Organization of the project .................................................................................. 4 1.4. ESVAC web-based application .............................................................................. 5 2. ESVAC sales data ..................................................................................... 5 2.1. Selection of data source ...................................................................................... 5 2.2. Antimicrobial substances used in veterinary medicine to be included in sales dataset ... 6 2.3. Variables to be collected for each VMP presentation ...............................................
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]